These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
148 related items for PubMed ID: 12822409
1. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia]. Hirayama Y, Sakamaki S, Takayanagi N, Tsuji Y, Sagawa T, Chiba H, Maeda M, Matsunaga T, Kato J, Niitsu Y. Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409 [Abstract] [Full Text] [Related]
5. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Dührsen U, Schmalzing M, Wunderle L, Binckebanck A, Hoelzer D, GMALL Study Group. Cancer; 2007 May 15; 109(10):2068-76. PubMed ID: 17429836 [Abstract] [Full Text] [Related]
6. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi-Deliliers G, Mannelli F, Levis A, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Spinelli O, Tosi M, Oldani E, Intermesoli T, Rambaldi A. J Clin Oncol; 2010 Aug 01; 28(22):3644-52. PubMed ID: 20606084 [Abstract] [Full Text] [Related]
9. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients. Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD. Leuk Res; 2005 Dec 01; 29(12):1381-6. PubMed ID: 15927253 [Abstract] [Full Text] [Related]
10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD. Ai Zheng; 2004 Dec 01; 23(12):1696-9. PubMed ID: 15601563 [Abstract] [Full Text] [Related]
12. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy]. Wang J, Huang X, Jiang B, Qin Y, Bao L, Jiang H, Chen H, Jia J, Yang S, Jiang Q. Zhonghua Xue Ye Xue Za Zhi; 2014 Feb 01; 35(2):120-5. PubMed ID: 24606652 [Abstract] [Full Text] [Related]
14. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia. Wernstedt P, Brune M, Andersson PO, Gustavsson B, Stockelberg D, Wadenvik H. Bone Marrow Transplant; 2002 Dec 01; 30(12):971-3. PubMed ID: 12476293 [Abstract] [Full Text] [Related]
15. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J. Cancer Res; 2006 May 15; 66(10):5387-93. PubMed ID: 16707466 [Abstract] [Full Text] [Related]
19. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]. Zhang YF, Chen ZM, Lou JY, Ni WM, Wang YG, Meng HT, Tong HY, Qian WB, Jin J. Zhonghua Xue Ye Xue Za Zhi; 2011 Dec 15; 32(12):814-8. PubMed ID: 22339953 [Abstract] [Full Text] [Related]
20. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N, Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S, Narimatsu H, Miyazaki Y, Ohtake S, Jinnai I, Matsuo K, Naoe T, Ohno R, Japan Adult Leukemia Study Group. Br J Haematol; 2008 Nov 15; 143(4):503-10. PubMed ID: 18986386 [Abstract] [Full Text] [Related] Page: [Next] [New Search]